4//SEC Filing
Bolzon Bradley J PhD 4
Accession 0000899243-21-029271
CIK 0001674416other
Filed
Jul 20, 8:00 PM ET
Accepted
Jul 21, 5:21 PM ET
Size
21.6 KB
Accession
0000899243-21-029271
Insider Transaction Report
Form 4
Bolzon Bradley J PhD
Director
Transactions
- Sale
Common Shares
2021-07-19$125.67/sh−3,504$440,345→ 155,327 total(indirect: See Footnote) - Sale
Common Shares
2021-07-19$128.71/sh−700$90,094→ 148,831 total(indirect: See Footnote) - Sale
Common Shares
2021-07-19$126.41/sh−4,472$565,289→ 150,855 total(indirect: See Footnote) - Sale
Common Shares
2021-07-19$127.36/sh−1,324$168,619→ 149,531 total(indirect: See Footnote)
Holdings
- 104,874(indirect: See Footnote)
Common Shares
- 215,915(indirect: See Footnote)
Common Shares
- 5,614(indirect: See Footnote)
Common Shares
- 16,434(indirect: See Footnote)
Common Shares
- 622(indirect: See Footnote)
Common Shares
- 6,268(indirect: See Footnote)
Common Shares
Footnotes (13)
- [F1]The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F10]These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and dispositive power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
- [F11]These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and dispositive power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
- [F12]These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and dispositive power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
- [F13]These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. Each of VV V CAN GP and VV V CAN may be deemed to have voting and dispositive power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
- [F2]These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $125.00 to $125.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.
- [F5]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $126.00 to $126.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- [F6]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $127.02 to $127.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
- [F7]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $128.18 to $129.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
- [F8]These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and dispositive power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
- [F9]These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and dispositive power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001354345
Filing Metadata
- Form type
- 4
- Filed
- Jul 20, 8:00 PM ET
- Accepted
- Jul 21, 5:21 PM ET
- Size
- 21.6 KB